The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ergomed PLC

3 Oct 2023 15:20

 
FORM 8.3
 
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
 
 

1

KEY INFORMATION
 
(a) Full name of discloser: MELQART ASSET MANAGEMENT (UK) LTD
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

N/A

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Ergomed PLC
Use a separate form for each offeror/offeree
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken: 2023-10-02
For an opening position disclosure, state the latest practicable date prior to the disclosure
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? No
If it is a cash offer or possible cash offer, state “N/A”
 

2

POSITIONS OF THE PERSON MAKING THE DISCLOSURE
 
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
 
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
 
Class of relevant security: 1p ordinary

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

(2) Cash-settled derivatives:

995,510

1.95%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

995,510

1.95%

 
All interests and all short positions should be disclosed.
 
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
(b) Rights to subscribe for new securities (including directors’ and other employee options)
 
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
 
 

3

DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
The currency of all prices and other monetary amounts should be stated.
 
(a) Purchases and sales
 
Class of relevant security Purchase/sale Number of securities Price per unit (GBp)
 
 
 
(b) Cash-settled derivative transactions
 
Class of relevant security Product description Nature of dealing Number of reference securities Price per unit (GBp)
e.g. CFD e.g. opening/closing a long/short position, increasing/reducing a long/short position
1p ordinary CFD increasing a long position

8,699

1344 GBp
1p ordinary CFD increasing a long position

9,357

1344 GBp
 
(c) Stock-settled derivative transactions (including options)
 
(i) Writing, selling, purchasing or varying
 
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type Expiry date Option money paid/ received per unit
e.g. American, European etc.
 
 
(ii) Exercise
 
Class of relevant security Product description Exercising/ exercised against Number of securities Exercise price per unit
e.g. call option
 
 
 
(d) Other dealings (including subscribing for new securities)
 
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
 
 
 
 

4

OTHER INFORMATION
 
(a) Indemnity and other dealing arrangements
 
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None
 
 
(b) Agreements, arrangements or understandings relating to options or derivatives
 
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None
 
 
(c) Attachments
 
Is a Supplemental Form 8 (Open Positions) attached? No
 
 
Date of disclosure: 2023-10-03
Contact name: Ben Sharp
Telephone number: +44 (0)20 3826 4493
 
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
 
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231003637910/en/

Copyright Business Wire 2023

Date   Source Headline
4th Apr 20227:00 amRNSIssue of Consideration Shares
1st Apr 202211:25 amRNSTotal Voting Rights
29th Mar 20227:00 amRNSErgomed Preliminary Results 2021
9th Mar 20227:00 amRNSJohn Dawson CBE Appointed to Ergomed Board as NED
1st Mar 20227:00 amRNSTotal Voting Rights
28th Feb 20227:00 amRNSErgomed Notice of Preliminary Results
11th Feb 20224:06 pmRNSDirector's Dealing
9th Feb 20227:00 amRNSAcquisition of ADAMAS
2nd Feb 20225:47 pmRNSHolding(s) in Company
25th Jan 20227:00 amRNSErgomed 2021 Trading Update
4th Jan 20227:00 amRNSTotal Voting Rights and Block Listing Return
1st Dec 20217:00 amRNSTotal Voting Rights
25th Nov 20217:00 amRNSExercise of Options
23rd Nov 20211:10 pmRNSHoldings in Company
15th Nov 20217:00 amRNSErgomed to Present at Jefferies Conference 2021
1st Nov 20217:00 amRNSTotal Voting Rights
25th Oct 20217:00 amRNSExercise of Share Options and Total Voting Rights
21st Oct 202110:20 amRNSHolding(s) in Company
5th Oct 20217:10 amEQSErgomed (ERGO): US is now the biggest market in the mix
5th Oct 20217:01 amEQSCreo Medical (CREO): Initiation - Providing energy for endoscopic surgery
1st Oct 20217:00 amRNSTotal Voting Rights
28th Sep 20217:00 amRNSErgomed Interim results
1st Sep 20217:00 amRNSTotal Voting Rights
23rd Aug 20217:00 amRNSNotice of Interim Results
19th Aug 202112:06 pmRNSHolding(s) in Company
18th Aug 202112:24 pmRNSHolding(s) in Company
18th Aug 202112:09 pmRNSDirector dealings
12th Aug 20217:01 amEQSErgomed (ERGO): Momentum continues with EBITDA upgrades
2nd Aug 20217:00 amRNSTotal Voting Rights
27th Jul 20217:00 amRNSTrading Update
19th Jul 20217:00 amRNSAppointment of Joint Corporate Broker
1st Jul 20217:00 amRNSBlock listing Interim Review
1st Jul 20217:00 amRNSTotal Voting Rights
17th Jun 20214:28 pmRNSHolding(s) in Company
17th Jun 20217:05 amRNSBoard Change
14th Jun 20218:14 amEQSErgomed (ERGO): FY21e EBITDA 'materially ahead' of consensus
10th Jun 202110:00 amRNSResult of AGM
10th Jun 20217:00 amRNSAGM Statement
2nd Jun 20218:00 amEQSEdison Investment Research Limited: Ergomed (ERGO): What's next after stellar 2020 performance?
1st Jun 20217:00 amRNSTotal Voting Rights
28th May 20217:00 amRNSErgomed to Present at Jefferies Conference
14th May 202111:30 amRNSHolding(s) in Company
14th May 20217:00 amRNSNotice of AGM and Annual Report
10th May 20217:00 amRNSBoard Changes
4th May 20217:00 amRNSTotal Voting Rights
29th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSBoard Changes
26th Apr 20217:00 amRNSErgomed expands operations in Japan
1st Apr 20217:00 amRNSTotal Voting Rights
23rd Mar 20217:00 amRNSAudited Full Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.